Adagio Medical
8
1
1
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
12.5%
1 terminated/withdrawn out of 8 trials
83.3%
-3.2% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
iCLAS™ for Persistent Atrial Fibrillation
Role: lead
Pulsed Field Ablation and Pulsed Field CRyoAbLation in PErsistent AtriaL FibrilLation
Role: lead
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
Role: lead
VT Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
Role: lead
Cryoablation for Monomorphic Ventricular Tachycardia (CryoCure-VT)
Role: lead
Cryoablation for Monomorphic Ventricular Tachycardia
Role: lead
Investigation of the Adagio Cryoablation System in Patients With Atrial Fibrillation
Role: lead
Prospective, Multicenter, Investigation of the Adagio Cryoablation System in Subjects With Atrial Flutter
Role: lead
All 8 trials loaded